ADREVIEW
Drug
GE HEALTHCARE
Total Payments
$859,684
Transactions
184
Doctors
8
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $13,377 | 1 | 0 |
| 2019 | $3,344 | 1 | 0 |
| 2018 | $601,419 | 129 | 0 |
| 2017 | $241,544 | 53 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $853,768 | 168 | 99.3% |
| Travel and Lodging | $5,346 | 8 | 0.6% |
| Food and Beverage | $570.25 | 8 | 0.1% |
Payments by Type
Research
$853,768
168 transactions
General
$5,916
16 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ADREVIEW MYOCARDIAL IMAGING FOR RISK EVALUATION: A MULTICENTRE TRIAL TO GUIDE ICD IMPLANTATION INNYHA CLASS II AND III HEART FAILURE PATIENTS WITH LVEF BETWEEN 30 PERCENT AND 35 PERCENT. ADMIRE-ICD | GE HEALTHCARE | $573,244 | 0 |
| GE-122-020 | GE HEALTHCARE | $123,631 | 0 |
| MYOCARDIAL IMAGING FOR RISK EVALUATION | GE HEALTHCARE | $85,999 | 0 |
| THREE DIMENSIONAL NEURO-CARDIAC IMAGING USING I123 MIBG SINGE PHOTON EMISSION CONPUTED TOMOGRAPHY AND PLANAR IMAGING TO GUIDE PREMATURE VENTRICULAR CONTRACTION ABLATION | GE HEALTHCARE | $29,016 | 0 |
| AdreView Myocardial Imaging for Risk Evaluation - A multicentre trial to guide ICD implantation inNYHA class II and III heart failure patients with LVEF between 30 and 35 percent. ADMIRE-ICD | GE HEALTHCARE | $20,363 | 0 |
| BRAIN-HEART CONNECTION IN TAKOTSUBO CARDIOMYOPATHY | GE Healthcare | $16,721 | 0 |
| CARDIAC AUTONOMIC FUNCTION IN WOMAN WITH MICROVASCULAR CORONARY DYSFUNCTION | GE HEALTHCARE | $4,794 | 0 |
Top Doctors Receiving Payments for ADREVIEW
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $853,768 | 168 |
| , MD | Cardiovascular Disease | Madison, WI | $1,456 | 2 |
| Wayne Levy | Cardiovascular Disease | Seattle, WA | $1,285 | 2 |
| , MD | Interventional Cardiology | Oakland, CA | $1,280 | 2 |
| , M.D | Interventional Cardiology | Schaumburg, IL | $636.38 | 2 |
| , MD | Cardiovascular Disease | Charleston, SC | $532.37 | 2 |
| Chaan Ng | Diagnostic Radiology | Houston, TX | $479.37 | 2 |
| , MD, MPH | Cardiovascular Disease | Dallas, TX | $129.07 | 2 |
| , MD | Diagnostic Radiology | Dallas, TX | $118.49 | 2 |
Ad
Manufacturing Companies
- GE HEALTHCARE $842,963
- GE Healthcare $16,721
Product Information
- Type Drug
- Total Payments $859,684
- Total Doctors 8
- Transactions 184
About ADREVIEW
ADREVIEW is a drug associated with $859,684 in payments to 8 healthcare providers, recorded across 184 transactions in the CMS Open Payments database. The primary manufacturer is GE HEALTHCARE.
Payment data is available from 2017 to 2020. In 2020, $13,377 was paid across 1 transactions to 0 doctors.
The most common payment nature for ADREVIEW is "Unspecified" ($853,768, 99.3% of total).
ADREVIEW is associated with 7 research studies, including "ADREVIEW MYOCARDIAL IMAGING FOR RISK EVALUATION: A MULTICENTRE TRIAL TO GUIDE ICD IMPLANTATION INNYHA CLASS II AND III HEART FAILURE PATIENTS WITH LVEF BETWEEN 30 PERCENT AND 35 PERCENT. ADMIRE-ICD" ($573,244).